Explore the latest in Huntington disease, including advances in understanding its epidemiology, etiology, diagnosis, and management.
This Viewpoint describes clinical and political considerations for individuals diagnosed with neurodegenerative conditions during the preclinical or prodromal stage.
This JAMA Patient Page describes Huntington disease and its symptoms, diagnosis, prognosis, and treatment options.
This review examines data from human and animal studies of the altered huntingtin protein associated with Huntington disease to assess the risk-benefit profile of huntingtin-lowering therapies for the treatment of people with Huntington disease.
This study analyzes the decades-long early progression of Huntington disease and its dependence on CAG repeat length.
This cross-sectional study of 5 European cohort studies determines the prevalence of carriers of intermediate and pathological polyglutamine disease鈥揳ssociated alleles among the general population.
This study uses data from the Track and COHORT studies to examine an approach to planning prediagnosis clinical trials for Huntington disease.
This cross-sectional study investigates the association between brain metabolism and motor scores of patients with early Huntington disease.
This open-label, single-arm study evaluates the safety and explores the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease.
This Teachable Moment describes a case of a man readmitted to the hospital for complications with his ileostomy bag; after magnetic resonance imaging of his brain and appropriate testing, he was diagnosed with Huntington disease.
This randomized clinical trial compares the effects of deutetrabenazine vs placebo on chorea among patients with Huntington disease.
This case report describes a white man in his mid to late forties with a history of Huntington disease presented with acute painful left eye vision loss
This cohort study evaluates the use of measures associated with cytosine-adenine-guanine (CAG) expansion that can be determined to identify individuals with CAG expansion before the diagnosis of Huntington disease.
This study concludes that information on the causative events of Huntington disease might help identify biomarkers that could be used to facilitate clinical trials.
Dorsey et al determine the longitudinal change in clinical features among individuals with Huntington disease compared with controls.
Marder et al attempted to determine whether the MeDi modifies the time to clinical onset of Huntington disease (phenoconversion) in premanifest carriers participating in Prospective Huntington at Risk Observational Study (PHAROS) and to examine the effects of body mass index and caloric intake on time to phenoconversion.
Customize your 糖心vlog experience by selecting one or more topics from the list below.